Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: Implications for diabetic retinopathy

Sylvia H. Wilson, Margaret I. Davis, Sergio Caballero, Maria B. Grant

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Evidence suggests the involvement of growth hormone (GH), insulin-like growth factor I (IGF-I) and somatostatin in the pathology associated with diabetic retinopathy. We examined the effect of IGF-I on human retinal endothelial cell (HREC) survival following high glucose exposure and serum starvation, examined the signalling pathways mediating the protective effect of IGF-I on HREC, and characterized somatostatin receptor-induced retinal endothelial cell death. IGF-I (10 ng/ml) protected HREC from apoptosis induced by high glucose and serum starvation. Wortmannin, a specific inhibitor of phosphotidylinositol-3-kinase, blocks the ability of IGF-I to protect HREC from apoptosis. Incubation of HREC in serum-free medium caused a time-dependent increase in c-Jun N-terminal kinase (JNK) activity, and continuous culture of HREC in the presence of IGF-I or vascular endothelial growth factor (VEGF) prevented JNK activation and arrested apoptosis. Activation of tyrosine kinase receptors results in extracellular signal-related kinase (ERK) activation and activation of ERK is required for proliferation. Both IGF-I and VEGF produced a time- and concentration-dependent increase in the activation of ERK. Type 2 and type 3 somatostatin receptors have been implicated in cell-cycle arrest and apoptosis. Activation of the type 3 receptor in HREC resulted in cell death. These studies suggest that IGF-I is critical for HREC survival, and that somatostatin analogues acting through the type 3 receptor have direct effects on retinal endothelial cells. Furthermore, it appears that the therapeutic efficacy of somatostatin analogues lies not only in systemic inhibition of GH, but also in modulating local growth factor effects.

Original languageEnglish (US)
JournalGrowth Hormone and IGF Research
Volume11
Issue numberSUPPL. 1
StatePublished - 2001
Externally publishedYes

Fingerprint

Diabetic Retinopathy
Somatostatin
Insulin-Like Growth Factor I
Endothelial Cells
Phosphotransferases
Apoptosis
Starvation
Vascular Endothelial Growth Factor A
Growth Hormone
Cell Survival
Cell Death
Glucose
Somatostatin Receptors
Aptitude
JNK Mitogen-Activated Protein Kinases
Serum-Free Culture Media
Receptor Protein-Tyrosine Kinases
Cell Cycle Checkpoints
Serum
Intercellular Signaling Peptides and Proteins

Keywords

  • Cell behaviour
  • Diabetic retinopathy
  • Endothelial cells
  • Insulin-like growth factor I
  • Retina
  • Somatostatin analogues

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues : Implications for diabetic retinopathy. / Wilson, Sylvia H.; Davis, Margaret I.; Caballero, Sergio; Grant, Maria B.

In: Growth Hormone and IGF Research, Vol. 11, No. SUPPL. 1, 2001.

Research output: Contribution to journalArticle

@article{3c366eca40a34e75bc0ae23a45a50a3d,
title = "Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: Implications for diabetic retinopathy",
abstract = "Evidence suggests the involvement of growth hormone (GH), insulin-like growth factor I (IGF-I) and somatostatin in the pathology associated with diabetic retinopathy. We examined the effect of IGF-I on human retinal endothelial cell (HREC) survival following high glucose exposure and serum starvation, examined the signalling pathways mediating the protective effect of IGF-I on HREC, and characterized somatostatin receptor-induced retinal endothelial cell death. IGF-I (10 ng/ml) protected HREC from apoptosis induced by high glucose and serum starvation. Wortmannin, a specific inhibitor of phosphotidylinositol-3-kinase, blocks the ability of IGF-I to protect HREC from apoptosis. Incubation of HREC in serum-free medium caused a time-dependent increase in c-Jun N-terminal kinase (JNK) activity, and continuous culture of HREC in the presence of IGF-I or vascular endothelial growth factor (VEGF) prevented JNK activation and arrested apoptosis. Activation of tyrosine kinase receptors results in extracellular signal-related kinase (ERK) activation and activation of ERK is required for proliferation. Both IGF-I and VEGF produced a time- and concentration-dependent increase in the activation of ERK. Type 2 and type 3 somatostatin receptors have been implicated in cell-cycle arrest and apoptosis. Activation of the type 3 receptor in HREC resulted in cell death. These studies suggest that IGF-I is critical for HREC survival, and that somatostatin analogues acting through the type 3 receptor have direct effects on retinal endothelial cells. Furthermore, it appears that the therapeutic efficacy of somatostatin analogues lies not only in systemic inhibition of GH, but also in modulating local growth factor effects.",
keywords = "Cell behaviour, Diabetic retinopathy, Endothelial cells, Insulin-like growth factor I, Retina, Somatostatin analogues",
author = "Wilson, {Sylvia H.} and Davis, {Margaret I.} and Sergio Caballero and Grant, {Maria B.}",
year = "2001",
language = "English (US)",
volume = "11",
journal = "Endocrinology and Metabolism",
issn = "1096-6374",
publisher = "Churchill Livingstone",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues

T2 - Implications for diabetic retinopathy

AU - Wilson, Sylvia H.

AU - Davis, Margaret I.

AU - Caballero, Sergio

AU - Grant, Maria B.

PY - 2001

Y1 - 2001

N2 - Evidence suggests the involvement of growth hormone (GH), insulin-like growth factor I (IGF-I) and somatostatin in the pathology associated with diabetic retinopathy. We examined the effect of IGF-I on human retinal endothelial cell (HREC) survival following high glucose exposure and serum starvation, examined the signalling pathways mediating the protective effect of IGF-I on HREC, and characterized somatostatin receptor-induced retinal endothelial cell death. IGF-I (10 ng/ml) protected HREC from apoptosis induced by high glucose and serum starvation. Wortmannin, a specific inhibitor of phosphotidylinositol-3-kinase, blocks the ability of IGF-I to protect HREC from apoptosis. Incubation of HREC in serum-free medium caused a time-dependent increase in c-Jun N-terminal kinase (JNK) activity, and continuous culture of HREC in the presence of IGF-I or vascular endothelial growth factor (VEGF) prevented JNK activation and arrested apoptosis. Activation of tyrosine kinase receptors results in extracellular signal-related kinase (ERK) activation and activation of ERK is required for proliferation. Both IGF-I and VEGF produced a time- and concentration-dependent increase in the activation of ERK. Type 2 and type 3 somatostatin receptors have been implicated in cell-cycle arrest and apoptosis. Activation of the type 3 receptor in HREC resulted in cell death. These studies suggest that IGF-I is critical for HREC survival, and that somatostatin analogues acting through the type 3 receptor have direct effects on retinal endothelial cells. Furthermore, it appears that the therapeutic efficacy of somatostatin analogues lies not only in systemic inhibition of GH, but also in modulating local growth factor effects.

AB - Evidence suggests the involvement of growth hormone (GH), insulin-like growth factor I (IGF-I) and somatostatin in the pathology associated with diabetic retinopathy. We examined the effect of IGF-I on human retinal endothelial cell (HREC) survival following high glucose exposure and serum starvation, examined the signalling pathways mediating the protective effect of IGF-I on HREC, and characterized somatostatin receptor-induced retinal endothelial cell death. IGF-I (10 ng/ml) protected HREC from apoptosis induced by high glucose and serum starvation. Wortmannin, a specific inhibitor of phosphotidylinositol-3-kinase, blocks the ability of IGF-I to protect HREC from apoptosis. Incubation of HREC in serum-free medium caused a time-dependent increase in c-Jun N-terminal kinase (JNK) activity, and continuous culture of HREC in the presence of IGF-I or vascular endothelial growth factor (VEGF) prevented JNK activation and arrested apoptosis. Activation of tyrosine kinase receptors results in extracellular signal-related kinase (ERK) activation and activation of ERK is required for proliferation. Both IGF-I and VEGF produced a time- and concentration-dependent increase in the activation of ERK. Type 2 and type 3 somatostatin receptors have been implicated in cell-cycle arrest and apoptosis. Activation of the type 3 receptor in HREC resulted in cell death. These studies suggest that IGF-I is critical for HREC survival, and that somatostatin analogues acting through the type 3 receptor have direct effects on retinal endothelial cells. Furthermore, it appears that the therapeutic efficacy of somatostatin analogues lies not only in systemic inhibition of GH, but also in modulating local growth factor effects.

KW - Cell behaviour

KW - Diabetic retinopathy

KW - Endothelial cells

KW - Insulin-like growth factor I

KW - Retina

KW - Somatostatin analogues

UR - http://www.scopus.com/inward/record.url?scp=0035378816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035378816&partnerID=8YFLogxK

M3 - Article

C2 - 11527089

AN - SCOPUS:0035378816

VL - 11

JO - Endocrinology and Metabolism

JF - Endocrinology and Metabolism

SN - 1096-6374

IS - SUPPL. 1

ER -